George Buchman, Ph.D.
Research Fellow at Catalent Biologics
Dr. Buchman joined Catalent through its acquisition of Paragon Gene Therapy in 2019. He has more than 30 years of experience in the biotech industry and has held roles at companies including Life Technologies (now Thermo Fisher), Celera Genomics and GeneLogic. Dr. Buchman obtained a bachelor’s degree in biochemistry from Albright College, Reading, Pennsylvania, and a doctorate in biochemistry from University of Maryland.